

NHS Grampian Formulary Group Decisions for SMC advice published April 2025



This document summarises the decisions of the NHS Grampian Formulary Group for Scottish Medicines Consortium (SMC) advice published April 2025.

For the latest Formulary Group decisions see the [Grampian Area Formulary website](#).

15 April 2025

Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](#)

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
alectinib 150mg hard capsules (Alecensa®)	2749	As monotherapy as adjuvant treatment for adult patients with Stage IB (tumours ≥ 4 cm) to IIIA (7th edition of the UICC/AJCC-staging system) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following complete tumour resection.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/04/2025
bimekizumab 160mg, 320mg solution for injection in pre-filled syringe, pre-filled pen (Bimzelx®)	2698	For the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. SMC restriction: for use in adult patients with active moderate to severe HS for whom adalimumab is contraindicated or otherwise unsuitable, including those who have failed to respond or have lost response to prior adalimumab treatment.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/04/2025
dapagliflozin 10mg film-coated tablets (Forxiga®)	2763	In adults for the treatment of chronic kidney disease (CKD). SMC restriction: in patients having individually optimised standard care (including angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, unless these are contraindicated or not tolerated), and either, at the start of treatment: - an estimated glomerular filtration rate (eGFR) of 20mL/min/1.73m ² up to 45mL/min/1.73m ² , or - an eGFR of 45mL/min/1.73m ² up to 90mL/min/1.73m ² and either: o A urine albumin-to-creatinine ratio (uACR) of 22.6mg/mmol or more, or o Type 2 Diabetes Mellitus (T2DM).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/04/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
elafibranor 80mg film-coated tablets (Iqirvo®)	2714	For the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/04/2025
eplontersen 45mg/0.8mL solution for injection in pre-filled pen (Wainzua®)	2755	For the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/04/2025
futibatinib 4mg film-coated tablets (Lytgobi®)	2661	As monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/04/2025
tebentafusp 200micrograms/mL concentrate for solution for infusion (Kimmtrak®)	2746	As monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.	Not routinely available as not recommended for use in NHS Scotland, SMC 2746 https://scottishmedicines.org.uk/media/9088/tebentafusp-kimmtrak-resub-final-march-2025-amended-030425-for-website.pdf	15/04/2025